이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in FESS

2026년 7월 21일 업데이트: Ain Shams University

Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in Adult Undergoing Functional Endoscopic Sinus Surgery.

Emergence agitation after sinus surgery is a common postoperative complication characterized by confusion, disorientation, and potentially violent behavior as a patient wakes from general anesthesia.This study compare the effect of nebulized dexmedetomidine versus nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

This study aims to compare preoperative nebulized dexmedetomidine and nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

연구 개요

상태

초대로 등록

정황

상세 설명

Type of Study: Prospective, randomized, double-blind, comparative clinical study.

Study Setting: Ain Shams University hospitals, Cairo, Egypt. Study Period: 6-12 months. Study Population: Adult patients scheduled for elective functional endoscopic sinus surgery.

Sampling Method: Random sampling Sample Size Based on the results of Ahmed et al 2022, with the mean VAS in patients treated with magnesium sulphate 7.2 ± 1.9 while the mean in Dexmedetomedine group 2.7 ± 0.9 Alpha error 5%,power of study 80% the required sample size is 50 patients, 25 patients in each group. The program for sample size calculation is STATA 10.

Ethical Considerations:

The study protocol will receive ethical approval from the Research Ethical Committee, Faculty of Medicine Ain Shams University. Informed consent will be obtained from all participants before starting study.

Randomization and blinding:

Group allocation will be contained in sequentially numbered, sealed opaque envelopes, which will be opened by the primary investigator. the data analyzer will be blinded about the study group.

Study Procedures:

All patients will be assessed preoperatively by careful history taking, airway examination and systemic examination. Complete blood count (CBC), coagulation profile, liver and kidney function tests for all patients and electrocardiogram (ECG) for patients older than 40 years of age will be reviewed from patients medical records. A written informed consent will be signed by all patients before the surgery. All patients will be admitted after completing fasting hours for both solid food and clear fluids. Upon arrival to the operating room (OR), IV access of the size 20 gauge (G) will be inserted..

In the preoperative holding area, heart rate (HR), mean blood pressure (MBP) and peripheral blood oxygen saturation (SpO2) will be measured immediately before nebulization either dexmedetomidine or magnesium sulphate,.and regulary every 5 minutes until the end of nebulization.

Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation and the patients in Group M will be nebulized with 250 mg nebulized magnesium sulfate completed to 3 ml using normal saline. The solution for nebulization will be administered by an anesthesiologist.

All patients will be monitored with a five-lead ECG, non-invasive blood pressure (NIBP) measurement and finger pulse oximetry. Baseline vital data (MAP, HR, and oxygen saturation (SO2)) will be recorded. HR and SO2 will be monitored continuosly and BP will be measured every 5 minutes (min) till the end of the surgery.

All patients will be premedicated with 0.03 mg/kg IV midazolam. Preoxygenation will be performed using 100% oxygen at a fresh gas flow (FGF) of 10 L/min via face mask for 3 minutes, followed by induction of general anesthesia.

Anesthesia will be induced with fentanyl 2 mcg/kg and propofol 2 mg/kg. Tracheal intubation will be facilitated by atracurium 0.5 mg/kg.

Both groups will be mechanically ventilated using volume control mode with tidal volume 7-10 ml/kg/min, positive end-expiratory pressure (PEEP) 5 cmH2O and oxygen-air mixture with fraction of inspired oxygen (FiO2) 50% and FGF of 3 L/min, and respiratory rate adjusted with target end-tidal carbon dioxide (ET CO2) 30-40 mmHg. 0.1 mg/kg IV atracurium will be given as needed to maintain muscle relaxation. 0.5 mcg/kg fentanyl will be given if HR or MAP increase ≥20% from their basal value. HR and MAP ≤20% of the basal value will be treated with needed doses of atropine and ephedrine, respectively. All patients will be extubated in the operating room and transferred to postanesthesia care unit (PACU).

Presence of emergence agitation will note in first 30 minutes in PACU using Aono's four-point scale scores after anesthesia.

Aono's four-point scale is used to assess post-anesthesia emergence agitation, where a score of 1 is calm, 2 is not calm but easily consoled, 3 is moderately agitated or restless, and 4 is combative, excited, or disoriented. Scores of 3 and 4 are generally considered to represent the presence of agitation and at this stage of agitation search for the cause and manage it .

In the postoperative ward, patients were also monitored for any drug-related side effects.

End point of study : After discharge of patients from PACU. The main researcher (Haidy Atef ) of the study will be the principal investigator responsible for the preparation and conduct of the study under supervision of the director (Prof. Dr. Moustafa Kamel) and co-directors(Prof. Dr. Hany Abdelfattah, Prof. Dr. Aktham Adel, Dr. Ahmed Saoudy). Each member of the team will ensure that the study is conducted according to the protocol approved in their meetings that will be arranged on regular basis. Results of the study and any complications that might occur during the study will be recorded and reported by the principal investigator and revised by the director and co-directors.

Statistical Analysis The collected data will be revised, coded and introduced to a PC using statistical package for social science (SPSS 23). Data will be presented as mean and standard deviation (±SD) for quantitative parametric data, median and range for quantitative non-parametric data and as numbers and percentage for qualitative data. Suitable analysis will be done according to the type of data obtained. P< 0.05 will be considered significant.

연구 유형

중재적

등록 (추정된)

50

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Cairo, 이집트
        • Ain shams university hospitals

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  1. Adult patients between 21 and 50 years of age undergoing elective functional endoscopic sinus surgery.
  2. American Society of Anesthesiologists physical status classification (ASA) I and II.

Exclusion Criteria:

  1. Patient's refusal.
  2. Complicated sinus surgery.
  3. History of allergy to any of the study drugs.
  4. Baseline HR≤60 beat/min.
  5. Baseline mean arterial pressure (MAP)≤70 mmHg.
  6. Psychiatric illness.
  7. Cerebrovascular insufficiency.
  8. Pregnancy.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 상영
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group D (Dexmedetomedine)
Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation
Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation.The solution for nebulization will be administered by an anesthesiologist.
다른 이름들:
  • 선행
실험적: Group M ( Magnesium Sulphate)
Group M will be nebulized with 250 mg nebulized magnesium sulfate completed to 3 ml using normal saline
Patients in Group M will be nebulized with 250 mg nebulized magnesium sulphate completed to 3 ml using normal saline 30 min before operation . The solution for nebulization will be administered by an anesthesiologist.
다른 이름들:
  • 황산마그네슘

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The primary endpoint will Visual Analogue Scale (VAS)score after anesthesia
기간: 30 minutes after operation in PACU
Pain will be assessed by VAS Score where 0 is no pain and 10 is the worst pain possible
30 minutes after operation in PACU

2차 결과 측정

결과 측정
측정값 설명
기간
The recovery time
기간: 30 minutes after operation in PACU
The time needed to discharge the patient from the PACU
30 minutes after operation in PACU
Aono's four-point score will assessed as secondary endpoints.
기간: 30 minutes after operation in PACU
Aono's four-point scale is used to assess post-anesthesia emergence agitation, where a score of 1 is calm, 2 is not calm but easily consoled, 3 is moderately agitated or restless, and 4 is combative, excited, or disoriented.
30 minutes after operation in PACU
The number, severity, and duration of agitation episode.
기간: 30 minutes after operation in PACU
The number, severity, and duration of agitation episode.
30 minutes after operation in PACU

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Haidy A Fekry, MBBCH,MSc, Ain Shams University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 22일

기본 완료 (추정된)

2026년 7월 22일

연구 완료 (추정된)

2027년 1월 22일

연구 등록 날짜

최초 제출

2026년 4월 25일

QC 기준을 충족하는 최초 제출

2026년 6월 28일

처음 게시됨 (실제)

2026년 7월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 21일

마지막으로 확인됨

2026년 4월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data underlying the study results will be made available upon reasonable request from qualified researches.

IPD 공유 기간

Within 6-12 months and for up to 5 years

IPD 공유 액세스 기준

Access will be granted to researchers who submit a methodologically sound proposal to the principal investigator . Requestes should be directed to haidy.atef@med.asu.edu.eg.

IPD 공유 지원 정보 유형

  • 연구_프로토콜

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다